Gavín, CarlosJ Blanco, FranciscoL Pablos, JoséCaracuel, Miguel ARosas, JoséGómez-Barrena, EnriqueNavarro, FranciscoCoronel, María PilarGimeno, Mercedes2025-01-072025-01-072021-07-211178-7090https://hdl.handle.net/10668/25741To assess the efficacy and safety of a single injection of a new formulation of hyaluronic acid (MPS-HA2%) in patients with symptomatic knee osteoarthritis after 12 months' follow-up. Prospective, single-arm, multicentre, open-label, 12-month follow-up study. Patients with Kellgren-Lawrence (KL) 2-3 and visual analogue scale (VAS) pain scores of ≥40- A total of 101 patients (mean age: 68 years; 74% female; and 78% overweight) were included. The mean reduction in pain at 12 months was 37.7%; the total WOMAC score improved by 36.5% and the pain, stiffness and physical function subscores returned improvements of 32.1%, 34.1% and 32.7%, respectively (p=0.0001 with respect to baseline). At 12 months, a statistically significant 62.2% of patients obtained an improvement equal to or greater than the MCII. The mean PGA score at baseline was 2.44 and 1.46 at 12 months (p With just a single intra-articular injection, this not controlled trial suggests that MPS-HA2% is effective 12 months after the procedure in most cases. Patient tolerability and safety were both optimal (NCT03852914).enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/hyaluronic acidosteoarthritispainviscosupplementationresearch article34321921open access10.2147/JPR.S321841PMC8312328https://www.dovepress.com/getfile.php?fileID=71894https://pmc.ncbi.nlm.nih.gov/articles/PMC8312328/pdf